The earnings call reflects a generally positive outlook with notable revenue and EBITDA growth, successful product launches, and strategic advancements in biosimilars. However, challenges such as the decline in AvKARE revenues, potential tariff impacts, and uncertainty in the RYTARY generics market were acknowledged.

Company Guidance -

Q3 2025

During the Amneal Pharmaceuticals Second Quarter 2025 Earnings Call, the company reported strong financial performance and raised its 2025 guidance. Amneal achieved Q2 revenues of $720 million and an adjusted EBITDA of $184 million. The company anticipates 2025 total revenues between $3 billion to $3.1 billion, with adjusted EBITDA revised to $665 million to $685 million, and adjusted EPS increased to $0.70 to $0.75. The strategic focus includes launching 20-30 new generics annually, expanding biosimilar offerings, and commercializing new specialty products like CREXONT and Brekiya. Amneal projects peak U.S. sales for CREXONT at $300 million to $500 million, and Brekiya at $50 million to $100 million. The company highlighted its continued diversification into innovative medicines, underscoring ongoing efforts in manufacturing expansion and strategic partnerships, such as with Metsera, to drive long-term growth. Amneal also succeeded in refinancing $2.7 billion of debt, reducing interest costs by over $33 million annually, and extending maturities to 2032, further strengthening its financial position.

Strong Revenue and EBITDA Growth

Amneal Pharmaceuticals reported Q2 revenues of $720 million and adjusted EBITDA of $184 million, marking a 3% revenue growth and a 13% increase in EBITDA compared to the previous year. Adjusted EPS grew by 56%.

Increased 2025 Financial Guidance

The company raised its 2025 guidance, expecting revenues between $3 billion to $3.1 billion and adjusted EBITDA between $665 million and $685 million. Adjusted EPS is projected to be between $0.70 and $0.75.

Successful Launches in Specialty Segment

CREXONT for Parkinson's disease exceeded expectations with a 2% U.S. market share and is on track for 3% by year-end. Brekiya autoinjector for severe migraine received FDA approval and is expected to be a $50 million to $100 million peak sales opportunity.

Advancements in Biosimilars

Amneal has 3 biosimilars commercialized and 5 more in development, with expectations to have 6 marketed biosimilars by 2027. The biosimilar XOLAIR represents a significant opportunity.

Debt Refinancing

Amneal successfully refinanced $2.7 billion in debt, reducing annual interest costs by over $33 million and extending maturities to 2032.

Amneal Pharmaceuticals (AMRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AMRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 07, 2025	2025 (Q3)	0.16 / -	0.16	―	―	―
Aug 05, 2025	2025 (Q2)	0.17 / 0.25	0.16	56.25% (+0.09)
May 02, 2025	2025 (Q1)	0.15 / 0.21	0.14	50.00% (+0.07)
Feb 28, 2025	2024 (Q4)	0.15 / 0.12	0.14	-14.29% (-0.02)
Nov 08, 2024	2024 (Q3)	0.13 / 0.16	0.19	-15.79% (-0.03)
Aug 09, 2024	2024 (Q2)	0.15 / 0.16	0.19	-15.79% (-0.03)
May 03, 2024	2024 (Q1)	0.09 / 0.14	0.12	16.67% (+0.02)
Mar 01, 2024	2023 (Q4)	0.09 / 0.14	0.23	-39.13% (-0.09)
Nov 07, 2023	2023 (Q3)	0.13 / 0.19	0.14	35.71% (+0.05)
Aug 04, 2023	2023 (Q2)	0.10 / 0.19	0.19	0.00% (0.00)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AMRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$7.96	$8.13	+2.14%
May 02, 2025	$7.74	$7.97	+2.97%
Feb 28, 2025	$8.38	$8.67	+3.46%
Nov 08, 2024	$8.61	$8.73	+1.39%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.